NASDAQ · IPSC
Century Therapeutics, Inc.
$1.46-$0.04 (-2.67%)
Century Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.97% below the high.
Loading market information…
NASDAQ · TELO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Telomir Pharmaceuticals, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 38.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Telomir Pharmaceuticals, Inc. Common Stock’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -$0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Telomir Pharmaceuticals, Inc. Common Stock’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Feb 4, 2025 | -$0.10-100.0% vs estimate | $18.79M |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.20-300.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $4.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.46-$0.04 (-2.67%)
Century Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.97% below the high.
$1.42$0.00 (0.0%)
Equillium, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.89% below the high.
$1.60+$0.07 (+4.58%)
INmune Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.46% below the high.
$10.99-$1.03 (-8.57%)
Coeptis Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.67% below the high.
$0.74-$0.02 (-2.49%)
Barinthus Biotherapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 59.56% below the high.
$1.50-$0.10 (-6.25%)
CEL-SCI Corporation’s quoted price sits in the lower half of its reported 52-week range, 80.77% below the high.
$0.88+$0.05 (+5.73%)
Karyopharm Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.99% below the high.
$0.62+$0.02 (+2.48%)
Genenta Science S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 80.32% below the high.
